Nanoform announced it has signed an agreement to manufacture GMP (Good Manufacturing Practice) nanoformed material for a European headquartered international company. This follows the Letter of Intent (LOI), signed between the parties in June 2021, to nanoform and develop, manufacture, and commercialize an improved version of a current blockbuster drug. In Third Quarter Nanoform signed 6 new customer non-GMP projects, taking the total for the first nine months of 2021 to 14 signed customer non-GMP projects (10 in 2020, 2 in 2019). Nanoform has now achieved its near-term business target of At least 12 new non-GMP customer projects and at least one new GMP customer project in 2021. The company has therefore achieved all near-term business targets for 2021. The value of the GMP and non-GMP projects are according to Nanoforms guided business model, ?0.5 million to ?10 million per GMP project and ?0.05 million to ?0.5 million per non-GMP project. The announced GMP agreement is for early clinical development and therefore in the lower end of the company GMP guidance range. The final contractual terms for commercialization will be negotiated as the project progresses.